Multiple Sclerosis Research at the University of Chicago
Neurologists at the University of Chicago are always studying new ways to diagnose and treat multiple sclerosis, and have consistently been at the forefront of advancements in autoimmune diseases. In 1993, our researchers helped develop and test interferon, the first FDA-approved treatment for multiple sclerosis. This "disease-modifying" therapy reduces exacerbations, improves function and memory, and lowers death rates. In the past two decades, seven new medications have been approved for new and relapsing disease. In addition to offering these therapies, our neurologists are directly involved in ongoing clinical trials to determine the effectiveness of the next generation of multiple sclerosis medications and diagnostic tools.
» Learn more about clinical trials for multiple sclerosis at the University of Chicago Medicine.
Translating MS Research from "Bench to Bedside"
At the University of Chicago, our specialists are dedicated to translating biomedical discoveries from laboratory findings to innovative therapies. Because the physicians at the University of Chicago Medicine Multiple Sclerosis Clinic are the same research scientists leading the search for a cure, they bring a unique understanding of complex treatments to patient care. In addition to having access to the latest medications, they understand which treatment option is best for each course of MS and, through a personalized approach to care, can identify the best therapy for each patient.